CN110832327A - 诊断性晚期糖基化终末产物抗体 - Google Patents

诊断性晚期糖基化终末产物抗体 Download PDF

Info

Publication number
CN110832327A
CN110832327A CN201880044776.XA CN201880044776A CN110832327A CN 110832327 A CN110832327 A CN 110832327A CN 201880044776 A CN201880044776 A CN 201880044776A CN 110832327 A CN110832327 A CN 110832327A
Authority
CN
China
Prior art keywords
age
patient
cells
sample
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880044776.XA
Other languages
English (en)
Chinese (zh)
Inventor
刘易斯·S·格鲁伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siwa Corp
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of CN110832327A publication Critical patent/CN110832327A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
CN201880044776.XA 2017-05-04 2018-05-03 诊断性晚期糖基化终末产物抗体 Pending CN110832327A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762501424P 2017-05-04 2017-05-04
US62/501,424 2017-05-04
US201762610003P 2017-12-22 2017-12-22
US62/610,003 2017-12-22
PCT/US2018/030931 WO2018204679A1 (en) 2017-05-04 2018-05-03 Diagnostic advanced glycation end-product antibodies

Publications (1)

Publication Number Publication Date
CN110832327A true CN110832327A (zh) 2020-02-21

Family

ID=62223287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044776.XA Pending CN110832327A (zh) 2017-05-04 2018-05-03 诊断性晚期糖基化终末产物抗体

Country Status (9)

Country Link
US (1) US20200150131A1 (https=)
EP (1) EP3619540A1 (https=)
JP (2) JP2020521117A (https=)
KR (2) KR20200003067A (https=)
CN (1) CN110832327A (https=)
AU (1) AU2018261622A1 (https=)
CA (1) CA3062082A1 (https=)
IL (1) IL270285B2 (https=)
WO (1) WO2018204679A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP3194439B1 (en) 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
EP3826670A1 (en) * 2018-07-23 2021-06-02 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
US20220396841A1 (en) * 2019-12-02 2022-12-15 Viome Life Sciences, Inc. Detection and elimination of aberrant cells
KR20210101481A (ko) * 2020-02-10 2021-08-19 한국과학기술연구원 초음파 출력부를 포함하는 노화세포 제거 장치
US20230181730A1 (en) 2020-05-01 2023-06-15 Siwa Corporation Methods of treating infections
AU2021326232A1 (en) * 2020-08-11 2023-04-13 Shenzhen Protgen Ltd. Young and undamaged human serum albumin improves longevity of human
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP7607149B2 (ja) * 2021-04-09 2024-12-26 カチョン ユニバーシティ オブ インダストリー－アカデミック コーオペレイション ファウンデイション グリコトキシン、グリコトキシンに結合した特定タンパク質、またはグリコトキシン－特定タンパク質複合体を含む神経変性疾患のバイオマーカー
EP4388016A1 (en) 2021-08-20 2024-06-26 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN118562721A (zh) * 2024-06-27 2024-08-30 广州市华代生物科技有限公司 一种基于全皮模型的糖化衰老模型及抗糖效果测试评价方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079825A (zh) * 1991-12-20 1993-12-22 洛克菲勒大学 体内高级糖基化终产物的免疫化学检测
US20110319499A1 (en) * 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
US20130243785A1 (en) * 2010-09-27 2013-09-19 Lewis Gruber Selective removal of age-modified cells for treatment of atherosclerosis
CN106163557A (zh) * 2014-01-28 2016-11-23 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
EP2582293B1 (en) * 2010-06-18 2016-04-20 DiagnOptics Holding B.V. Method and apparatus for determining an autofluorescence value of skin tissue.
JP2017527580A (ja) * 2014-09-12 2017-09-21 ザ プロクター アンド ギャンブル カンパニー 老化防止スキンケア組成物及びレジメン
US10358502B2 (en) * 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079825A (zh) * 1991-12-20 1993-12-22 洛克菲勒大学 体内高级糖基化终产物的免疫化学检测
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US20110319499A1 (en) * 2008-06-30 2011-12-29 The Johns Hopkins University Methods for the Detection of Advanced Glycation Endproducts and Markers for Disease
US20130243785A1 (en) * 2010-09-27 2013-09-19 Lewis Gruber Selective removal of age-modified cells for treatment of atherosclerosis
CN106163557A (zh) * 2014-01-28 2016-11-23 巴克老龄化研究所 用于杀死衰老细胞和用于治疗衰老相关疾病和病症的方法和组合物
WO2017065837A1 (en) * 2015-10-13 2017-04-20 Siwa Corporation Anti-age antibodies and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114624362A (zh) * 2022-03-17 2022-06-14 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 一种检测血清中晚期糖基化终末产物的试剂盒及其应用

Also Published As

Publication number Publication date
IL270285B1 (en) 2025-02-01
WO2018204679A1 (en) 2018-11-08
EP3619540A1 (en) 2020-03-11
KR20200003067A (ko) 2020-01-08
RU2019139256A3 (https=) 2022-01-18
IL270285A (en) 2019-12-31
US20200150131A1 (en) 2020-05-14
CA3062082A1 (en) 2018-11-08
AU2018261622A1 (en) 2019-12-12
KR20240006702A (ko) 2024-01-15
IL270285B2 (en) 2025-06-01
JP2023098996A (ja) 2023-07-11
JP2020521117A (ja) 2020-07-16
RU2019139256A (ru) 2021-06-07

Similar Documents

Publication Publication Date Title
CN110832327A (zh) 诊断性晚期糖基化终末产物抗体
US10775383B2 (en) PD-L1 antibodies and uses thereof
US11833202B2 (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
Ocana et al. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
US20190315846A1 (en) Antibodies to Human Alpha-Synuclein
TR201902972T4 (tr) Kanseri tespit etmek için yöntem.
US12055552B2 (en) Method for diagnosis based on circulating extracellular vesicles
US12545728B2 (en) Treatment of cancer metastasis by targeting exosome proteins
JP2023553247A (ja) がん診断のための組成物および方法
RU2788905C2 (ru) Диагностические антитела к конечным продуктам глубокого гликирования
EP3919520B1 (en) Antibody and functional fragment thereof
JP5176229B2 (ja) アレルギー疾患の治療薬且つ治療効果のマーカー
JP7773526B2 (ja) 新規α－シンヌクレイン結合抗体又はその抗原結合部分
JP7686748B2 (ja) 細胞表面部分の発現又はクラスター化を検出するための方法
Lu Developing blood-based biomarkers of disease progression in Amyotrophic Lateral Sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200221

WD01 Invention patent application deemed withdrawn after publication